Patents by Inventor Anne G. Laurent Crawford

Anne G. Laurent Crawford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic compositions comprising human immunodeficiency virus type 2 (HIV-2) glycosylated and unglycosylated envelope proteins and their methods of preparation
    Patent number: 7507417
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: March 24, 2009
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé
  • Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80
    Patent number: 6984721
    Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2, particularly, the HIV-2 proteins gp300, p200, p90, and p80, and gp300 of SIV.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: January 10, 2006
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé
  • Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins GP300, P200, and P90/80
    Publication number: 20010006641
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp14O, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Application
    Filed: December 19, 2000
    Publication date: July 5, 2001
    Applicant: Institut Pasteur
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuille
  • Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
    Patent number: 6197496
    Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2 are disclosed. Particularly, the HIV-2 proteins, gp300, p200, p90, and p80, and gp300 of SIV are described.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: March 6, 2001
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Anne G. Laurent Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuillé
  • Immunogenic compositions comprising glycosylated and deglycosylated monomeric and dimeric forms of HIV-2 enveloped glycoproteins
    Patent number: 6056963
    Abstract: This invention is directed to a composition comprising one or more human immunodeficiency virus type 2 (HIV-2) envelope proteins and a pharmaceutically acceptable carrier. The proteins of the claimed invention are gp300, p200 and p90/80 of HIV-2. The composition is useful for the diagnostic assay of HIV-2 and as an antigen for the production of antibodies, for example.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 2, 2000
    Assignee: Institut Pasteur and Centre Nationale de la Recherche Scientifique (C.N.R.S.)
    Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuille